Search

everythinglearnresearchcommunity

for

Search:↓

In 2021, JAMA Dermatology published significant findings on skin conditions post-COVID vaccination, melanoma surveillance, atopic dermatitis treatments, and confirmed that sun protection does not harm bone health.

The drug showed promise in treating renal cell carcinoma with manageable side effects.

Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.

JAK inhibitors show promise in treating difficult skin diseases.

JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.

Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.

JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.

Upadacitinib improved multiple immune-related conditions in one patient.

Baricitinib effectively improved skin and hair conditions in a patient with alopecia areata and atopic dermatitis.

JAK inhibitors offer new hope for treating severe alopecia areata.

Janus Kinase inhibitors effectively induce remission in Ulcerative Colitis with an acceptable safety profile.

Baricitinib helps regrow hair in severe alopecia areata but has side effects like infections and headaches.

A patient's hair loss may be linked to their diabetes medication, Sitagliptin.

Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.

Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.

Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.

JAK inhibitors show promise for treating skin diseases effectively and safely.

Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.

Janus Kinase Inhibitors are promising new treatments for various skin conditions due to their effectiveness and safety.

Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.

JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.

Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.

JAK inhibitors effectively treat severe atopic dermatitis and alopecia areata.

Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.

Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.

Irish dermatologists urgently need guidelines for using JAK inhibitors in treating alopecia areata.

Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.